Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;9(5):e14779.
doi: 10.14814/phy2.14779.

Mirabegron: The most promising adipose tissue beiging agent

Jocelyn S Bel  1 , T C Tai  2   3   4   5 , Neelam Khaper  2   5   6 , Simon J Lees  2   6
Affiliations
Review

Mirabegron: The most promising adipose tissue beiging agent

Jocelyn S Bel et al. Physiol Rep. 2021 Mar.

Abstract

Accumulation of white adipose tissue (WAT) underlies the obesity epidemic, leading to current therapeutic techniques that are being investigated for their ability to activate/"beige" this tissue. Adipose tissue (AT) beiging has been reported through intermittent cold exposure (CE), exercise, and β3-Adrenergic Receptor (β3AR) agonists. But how AT beiging can help in the treatment of metabolic disorders like obesity and type 2 diabetes (T2D) remains largely unexplored. This review summarizes recent research on the use of β3AR agonist, mirabegron (Myrbetriq®), in stimulating beiging in AT. Researchers have only recently been able to determine the optimal therapeutic dose of mirabegron for inducing beiging in subcutaneous/ inguinal WAT, where the benefits of AT activation are evident without the undesired cardiovascular side effects. To determine whether the effects that mirabegron elicits are metabolically beneficial, a comparison of the undisputed findings resulting from intermittent CE-induced beiging and the disputed findings from exercise-induced beiging was conducted. Given the recent in vivo animal and clinical studies, the understanding of how mirabegron can be metabolically beneficial for both lean and obese individuals is more clearly understood. These studies have demonstrated that circulating adipokines, glucose metabolism, and lipid droplet (LD) size are all positively affected by mirabegron administration. Recent studies have also demonstrated that mirabegron has similar outcomes to intermittent CE and displays more direct evidence for beiging than those produced with exercise. With these current findings, mirabegron is considered the most promising and safest β3AR agonist currently available that has the potential to be used in the therapeutic treatment of metabolic disorders, and future studies into its interaction with different conditions may prove to be useful as part of a treatment plan in combination with a healthy diet and exercise.

Keywords: Brown Adipose Tissue; Browning; Obesity; β3-Adrenergic Receptor Agonist.

PubMed Disclaimer

References

    1. Aldiss, P. , Betts, J. , Sale, C. , Pope, M. , Budge, H. , & Symonds, M. E. (2018). Exercise‐induced ‘browning’ of adipose tissues. Metabolism, 81, 63–70. 10.1016/j.metabol.2017.11.009 - DOI - PMC - PubMed
    1. Baskin, A. S. , Linderman, J. D. , Brychta, R. J. , McGehee, S. , Anflick‐Chames, E. , Cero, C. , Johnson, J. W. , O’Mara, A. E. , Fletcher, L. A. , Leitner, B. P. , Duckworth, C. J. , Huang, S. , Cai, H. , Garraffo, H. M. , Millo, C. M. , Dieckmann, W. , Tolstikov, V. , Chen, E. Y. , Gao, F. , … Cypess, A. M. (2018). Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3‐Adrenergic Receptor Agonist. Diabetes, 67, 2113–2125. 10.2337/db18-0462 - DOI - PMC - PubMed
    1. Boström, P. , Wu, J. , Jedrychowski, M. P. , Korde, A. , Ye, L. , Lo, J. C. , Rasbach, K. A. , Boström, E. A. , Choi, J. H. , Long, J. Z. , Kajimura, S. , Zingaretti, M. C. , Vind, B. F. , Tu, H. , Cinti, S. , Højlund, K. , Gygi, S. P. , & Spiegelman, B. M. (2012). A PGC1‐α‐dependent myokine that drives brown‐fat‐like development of white fat and thermogenesis. Nature, 481, 463–468. 10.1038/nature10777 - DOI - PMC - PubMed
    1. Carpentier, A. C. , Blondin, D. P. , Virtanen, K. A. , Richard, D. , Haman, F. , & Turcotte, É. E. (2018). Brown Adipose Tissue Energy Metabolism in Humans. Frontiers in Endocrinology, 9, 447. 10.3389/fendo.2018.00447 - DOI - PMC - PubMed
    1. Chapple, C. R. , Dvorak, V. , Radziszewski, P. , Van Kerrebroeck, P. , Wyndaele, J. J. , Bosman, B. , Boerrigter, P. , Drogendijk, T. , Ridder, A. , Van Der Putten‐Slob, I. , & Yamaguchi, O. (2013). A phase II dose‐ranging study of mirabegron in patients with overactive bladder. International Urogynecology Journal, 24, 1447–1458. 10.1007/s00192-013-2042-x - DOI - PMC - PubMed

Publication types